Women are increasingly taking the lead at grand rounds, however, female grand lecturers are still markedly underrepresented ...

A blow for Getty ahead of its AI showdown with Stability AI and a licensing deal between Nokia and Samsung were among the big ...

Fintel reports that on January 16, 2025, Wolfe Research downgraded their outlook for Edwards Lifesciences (NYSE:EW) from Peer ...

Risk for bleeding events is significantly affected by DOAC score in patients with atrial fibrillation who have received TAVR.

Daniel J. Lippis, the Corporate Vice President for JAPAC at Edwards Lifesciences Corp (NYSE:EW), has disclosed recent stock ...

In 2024, the Hatch-Waxman Act continued to play a critical role in the U.S. pharmaceutical landscape, driving the dynamics between ...

Edwards Lifesciences (EW) stock faces a downgrade at Wolfe due to concerns over its TAVR market prospects. Read more here.

Wedgewood Partners, an investment management company, released its fourth-quarter 2024 investor letter. A copy of the letter ...

TPL and TSM were top performers, while CDW and UnitedHealth were notable detractors for both the quarter and the year. Click ...

Wolfe Research downgraded Edwards Lifesciences (EW) to Underperform from Peer Perform with a $60 price target The firm says its core ...

Capital Investment Advisors LLC lowered its stake in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 2.4% during the fourth quarter, according to its most recent disclosure with the ...

This was the stock's fourth consecutive day of losses.